ZA936260B - Novel antibodies for conferring passive immunity against infection by a pathogen in man - Google Patents

Novel antibodies for conferring passive immunity against infection by a pathogen in man

Info

Publication number
ZA936260B
ZA936260B ZA936260A ZA936260A ZA936260B ZA 936260 B ZA936260 B ZA 936260B ZA 936260 A ZA936260 A ZA 936260A ZA 936260 A ZA936260 A ZA 936260A ZA 936260 B ZA936260 B ZA 936260B
Authority
ZA
South Africa
Prior art keywords
pathogen
man
immunity against
against infection
passive immunity
Prior art date
Application number
ZA936260A
Inventor
Mitchell Stuart Gross
Martin Rosenberg
Mark Hurle
Jerald Charles Sadoff
Steven Hoffman
Daniel R Sylvester
Yupin Charoenvit
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of ZA936260B publication Critical patent/ZA936260B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA936260A 1992-09-09 1993-08-26 Novel antibodies for conferring passive immunity against infection by a pathogen in man ZA936260B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94165492A 1992-09-09 1992-09-09

Publications (1)

Publication Number Publication Date
ZA936260B true ZA936260B (en) 1994-03-18

Family

ID=25476840

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA936260A ZA936260B (en) 1992-09-09 1993-08-26 Novel antibodies for conferring passive immunity against infection by a pathogen in man

Country Status (9)

Country Link
EP (1) EP0659192A4 (en)
JP (1) JPH08500979A (en)
KR (1) KR950703573A (en)
CN (1) CN1087681A (en)
AU (1) AU4851193A (en)
CA (1) CA2143417A1 (en)
NZ (1) NZ256232A (en)
WO (1) WO1994005690A1 (en)
ZA (1) ZA936260B (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0782626A1 (en) * 1994-09-19 1997-07-09 Rijkslandbouwuniversiteit Wageningen Gene constructs encoding crop-protecting agents, as well as transformed plants containing and expressing such constructs, and methods of controlling plague organisms and pathogens in crops
SE9500148D0 (en) * 1995-01-18 1995-01-18 Bioinvent Internatioal Ab Antibodies for use in cancer therapy and diagnosis
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AU2008200400B2 (en) * 2001-01-17 2012-06-07 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
PL364623A1 (en) * 2001-01-17 2004-12-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US6979446B2 (en) 2001-01-26 2005-12-27 Inhibitex, Inc. Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections
WO2004111233A1 (en) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha Process for producing antibody
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
WO2006106903A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
US10011858B2 (en) * 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
WO2006132363A1 (en) 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
JP5085322B2 (en) 2005-06-10 2012-11-28 中外製薬株式会社 Pharmaceutical composition containing sc (Fv) 2
KR101251157B1 (en) 2005-07-25 2013-04-10 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 B-cell reduction using cd37-specific and cd20-specific binding molecules
EP4342995A3 (en) 2006-03-31 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN105177091A (en) 2006-03-31 2015-12-23 中外制药株式会社 Antibody modification method for purifying bispecific antibody
EP2041178A2 (en) 2006-06-12 2009-04-01 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
RU2526512C2 (en) 2007-09-26 2014-08-20 Чугаи Сейяку Кабусики Кайся Modified constant region of antibody
RU2531754C2 (en) 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Immunotherapeutic agent combined with cd37, and its combination with bifunctional chemotherapeutic agent
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5787446B2 (en) 2009-03-19 2015-09-30 中外製薬株式会社 Antibody constant region variants
US8163283B2 (en) * 2009-09-03 2012-04-24 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
JP5837821B2 (en) 2009-09-24 2015-12-24 中外製薬株式会社 Antibody constant region variants
WO2011108714A1 (en) 2010-03-04 2011-09-09 中外製薬株式会社 Antibody constant region variant
AU2011330184B2 (en) 2010-11-17 2016-03-10 Chugai Seiyaku Kabushiki Kaisha Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor VIII
WO2013065708A1 (en) 2011-10-31 2013-05-10 中外製薬株式会社 Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
CN113045660B (en) 2013-03-13 2023-09-01 伊麦吉纳博公司 Antigen binding constructs to CD8
KR102441231B1 (en) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 Method for preparing polypeptide heteromultimers
FR3025517B1 (en) * 2014-09-10 2016-12-23 Repropharm LIGANDS POTENTIATING THE BIOACTIVITY OF GONADOTROPHINS
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
RU2765242C2 (en) 2015-08-07 2022-01-27 Имаджинаб, Инк. Antigen-binding constructs against target molecules
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
CA3004288A1 (en) 2015-12-28 2017-07-06 Nobuyuki Tanaka Method for promoting efficiency of purification of fc region-containing polypeptide
AU2017233658B2 (en) 2016-03-14 2023-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
CN117854601B (en) * 2024-03-04 2024-05-14 鲁东大学 A method for determining complementary regions based on gene type and amino acid sequence

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632909A (en) * 1983-10-31 1986-12-30 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies which block infectivity of malarial parasites to mosquitoes
JPS63267295A (en) * 1986-12-03 1988-11-04 Sumitomo Chem Co Ltd Human antibodies, antibody genes and corresponding recombinants

Also Published As

Publication number Publication date
CN1087681A (en) 1994-06-08
CA2143417A1 (en) 1994-03-17
EP0659192A4 (en) 1996-09-11
KR950703573A (en) 1995-09-20
NZ256232A (en) 1997-02-24
AU4851193A (en) 1994-03-29
EP0659192A1 (en) 1995-06-28
WO1994005690A1 (en) 1994-03-17
JPH08500979A (en) 1996-02-06

Similar Documents

Publication Publication Date Title
ZA936260B (en) Novel antibodies for conferring passive immunity against infection by a pathogen in man
EP0497471A3 (en) A technique for improving esd immunity
TW301244U (en) System for improving the fit of a hand in a glove
GB2265221B (en) Inductive sensors
IL96561A0 (en) Amorphous silicon sensor
HU9300010D0 (en) Glycoprotein vaccine named ehv-4
GB9110698D0 (en) Inductive displacement sensors
GB2252414B (en) Impact sensing device
GB9206203D0 (en) Inductive sensors
GB9202926D0 (en) A reinforcement device
AU111329S (en) A bottle
AU113967S (en) A bottle
AU111447S (en) A bottle
AU112350S (en) A Bottle
AU116783S (en) A bottle
AU110494S (en) A bottle
GB9225057D0 (en) A sensor
GB9211116D0 (en) Inductive sensor
GB9121891D0 (en) A device for gripping differently sized objects
GB9026694D0 (en) A damping device
GB9025142D0 (en) Intelligent vibration sensor
DK0575970T3 (en) Bag containing a concentrate
GB2296977B (en) Semi-conductor acceleration sensor
GB8925716D0 (en) Auxiliary device for a nursing bottle
IL127163A0 (en) A vaccine which provides protective immunity against a bacterial pathogen